Skip to main content
Premium Trial:

Request an Annual Quote

Cellexus Ltd. Acquires Cellexus Biosystems IP, Assets

NEW YORK (GenomeWeb News) – The investors in Cellexus Ltd. said yesterday that they have acquired the assets of Cellexus Biosystems Plc and have formed a new management team aimed at bringing the firm’s products to market.
 
Cellexus makes single-use bioreactors and cell-based technologies for biopharmaceutical research and production. The firm said that since the asset acquisition it has “made significant design and operational improvements to the CellMaker bioreactor systems.”
 
It also intends to launch a range of new products over the coming months including the CellMaker Regular for culture of E. Coli and Pichia cells and the CellMaker PLUS for culture of all cells including mammalian and insect.  
 
The Cambridgeshire, UK-based company said that it made the purchase in April, but did not disclose it until this week.

The Scan

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.

Study Uncovers Genetic Mutation in Childhood Glaucoma

A study in the Journal of Clinical Investigation ties a heterozygous missense variant in thrombospondin 1 to childhood glaucoma.

Gene Co-Expression Database for Humans, Model Organisms Gets Update

GeneFriends has been updated to include gene and transcript co-expression networks based on RNA-seq data from 46,475 human and 34,322 mouse samples, a new paper in Nucleic Acids Research says.

New Study Investigates Genomics of Fanconi Anemia Repair Pathway in Cancer

A Rockefeller University team reports in Nature that FA repair deficiency leads to structural variants that can contribute to genomic instability.